Frontier mental health research: psychedelics & drug studies

Key findings

• Ketamine can reduce depressive symptoms very fast — often within hours or a day after a single infusion. ^{10149 10152 10151 15070}
• A nasal form called esketamine has been tested in trials and has faster symptom improvement when added to an oral antidepressant; it is approved for some treatment‑resistant cases. ^{12156 15070 10153}
• Effects after one dose often do not last long. Symptoms commonly start to return after about one to two weeks, so clinics use repeated dosing to try to keep benefits. ^{15070 10149 10159}
• The overall evidence comes from randomized controlled trials, several clinical trials, and expert reviews, but many studies are small or short, so long‑term safety and the best treatment schedules are still uncertain. ^{10153 15070 10152 10159}
• Common short‑term side effects include brief dissociation (strange or dreamlike feelings), temporary rises in blood pressure, dizziness, and headache; these effects usually pass within a few hours after treatment. ^{10159 10152 10151}
• When ketamine is given in medical settings, evidence so far shows few clear cases of addiction or dependence, but the data are limited and some cases of tolerance or dependence have been reported. ^{8828 10153}
• One randomized trial found ketamine was at least as effective as electroconvulsive therapy (ECT) for nonpsychotic, treatment‑resistant major depression, but this does not settle which treatment is best for every person. ^{10160 10149}
• Scientists think ketamine works by blocking NMDA receptors and then boosting other glutamate receptors (AMPA) and growth signals in the brain, but the exact pathways are still being worked out. ^{10146 10147 10148}
• Some biological markers are unclear: a meta‑analysis found no consistent change in blood BDNF (a growth protein) after psychoplastogen drugs like ketamine, which shows a gap between animal models and measurable human blood changes. ^{15129 10146}
• People with depression view ketamine as promising but worry about its reputation, long‑term harms, and how clinics would monitor use; patients also report that non‑drug factors (like what they saw or did before sessions) can shape their ketamine experiences. ^{12365 15075}